In the race to develop next-generation antibody therapies for solid tumors, antibody drug conjugates (ADCs) are surging, while T-cell engagers…
BUSINESS
Fujifilm Launches New Japanese Avigan PIII Study for COVID-19
Fujifilm Toyama Chemical has commenced a new Japanese PIII clinical study of its antiviral Avigan (favipiravir) under fresh protocol, it said on April 21. The new study aims to investigate the safety and efficacy of the drug in patients with…
To read the full story
Related Article
- Fujifilm Ditches Avigan COVID-19 Program, Pulls Submission in Japan
October 17, 2022
- Fujifilm Drops Avigan’s Japan PIII Trial for COVID-19
March 14, 2022
- Plunge in COVID-19 Cases Stalling Japan Avigan Study by Few Months
November 5, 2021
- Advisory Panel Shelves Decision on Avigan, Says No Clear Efficacy Shown for COVID-19
December 22, 2020
- (Update) Avigan Filed for COVID-19 in Japan: Fujifilm
October 16, 2020
- Avigan Hits Primary Goal for Novel Coronavirus, Filing Eyed in October: Fujifilm
September 24, 2020
BUSINESS
- Chugai to Defer Domestic Supply of Elevidys amid Safety Review
July 25, 2025
- Chugai to Build New Research Building to Strengthen Process Development
July 25, 2025
- Chugai Drops Five Early-Stage Programs to Refocus Pipeline
July 25, 2025
- Pfizer Japan Recalls Syphilis Drug over Particulate Contamination
July 25, 2025
- Chugai Delivers Positive H1 Earnings on Innovative Drugs, Export Growth
July 25, 2025
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…